JP Morgan: This year, the Chinese healthcare industry has shown a significant rebound. We are optimistic about AKESO (09926), INNOVENT BIO (01801), and Jiangsu Hengrui Pharmaceuticals (01276).

JPMorgan released a research report stating that the Chinese healthcare industry has experienced a significant rebound so far this year, with the MSCI China Healthcare Index rising by around 50%. The bank believes that the Hang Seng Healthcare Index (HSHCI) could potentially reach or even surpass its high point in 2022/2023, around 4400 to 4600 points. JPMorgan believes that this year's industry rebound is mainly driven by several factors, including strong momentum in outbound licensing deals for innovative drugs, solid fundamentals of Chinese biotech and pharmaceutical companies, favorable domestic policy environment, and low investor positioning. The bank points out that due to the current strong trend likely to continue in the short term, stocks with upcoming catalysts this year have the potential to outperform the market, with positive outlook on AKESO (09926), INNOVENT BIO (01801), and Jiangsu Hengrui Pharmaceuticals (01276), while stocks with fewer catalysts include SKB BIO-B (06990), REMEGEN (09995), and JUNSHI BIO (01877).